Business Overview

CMS has been deeply engaged in the Chinese pharmaceutical market for over 30 years, and has always maintained its patient-centered philosophy. We are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.

We have built three major business segments: cardio-cerebrovascular and gastroenterology, dermatology and medical aesthetics, and ophthalmology. These divisions are run as independent business units, driving growth and cultivating an entrepreneurial spirit, whilst allowing them to benefit from the scale advantages and operational efficiencies inherent with being part of a larger group and empowering the divisions to gain leading positions in specialty markets.

We have a mature commercialization platform that is compliant with international standards, efficient, fosters resource-sharing among teams, includes a professional and highly qualified promotion team with strong execution capability, and extensive channel resources as well as a wide range of expert networks in specialty fields. This creates deep insights into clinical needs and deep experience in market access, academic promotion, government affairs and brand building, allowing CMS to build a long track-record of developing market-leading positions for a number of products.

We have been accelerating the development in the Southeast Asian market. Relying on our professional and experienced local management team, we continue to refine our business in Southeast Asia, which comprehensively covers “R&D, manufacturing, and commercialization”, empowering global pharmaceutical companies to enter the Southeast Asian market, opening up a new second growth curve for the Group.

Based on our commercialization platform and deep market understanding, we have deployed differentiated innovative products globally and efficiently promoted clinical development and commercialization of the products, so as to benefit patients.